Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026)

Regeneron Pharmaceuticals has reported Capital Expenditures for 18 years, with the latest figure at $240.2 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 9.68% year-over-year to $240.2 million in Q2 2026; TTM through Jun 2026 was $201.3 million, a 55.1% decrease from a year earlier, with the FY2025 full-year figure at $178.8 million, up 17.94% from the prior year.
• Capital Expenditures was $240.2 million for Q2 2026 at Regeneron Pharmaceuticals, up from $230.6 million in the prior quarter.
• The five-year high for Capital Expenditures was $404.7 million in Q3 2024, with the low at -$470.9 million in Q4 2025.
• Average Capital Expenditures over 5 years is $117.2 million, with a median of $165.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures plunged 260.98% in 2024, then jumped 1137.29% in 2025.
• Over 5 years, Capital Expenditures stood at $152.2 million in 2022, then soared by 65.18% to $251.4 million in 2023, then slumped by 260.98% to -$404.7 million in 2024, then declined by 16.36% to -$470.9 million in 2025, then soared by 151.01% to $240.2 million in 2026.
• The last three Capital Expenditures figures came in at $240.2 million (Q2 2026), $230.6 million (Q1 2026), and -$470.9 million (Q4 2025), per Business Quant data.